Not all saponins have a greater antiprotozoal activity than their related sapogenins

The antiprotozoal effect of saponins varies according to both the structure of the sapogenin and the composition and linkage of the sugar moieties to the sapogenin. The effect of saponins on protozoa has been considered to be transient as it was thought that when saponins were deglycosilated to sapogenins in the rumen they became inactive; however, no studies have yet evaluated the antiprotozoal effect of sapogenins compared to their related saponins. The aims of this study were to evaluate the antiprotozoal effect of eighteen commercially available triterpenoid and steroid saponins and sapogenins in vitro, to investigate the effect of variations in the sugar moiety of related saponins and to compare different sapogenins bearing identical sugar moieties. Our results show that antiprotozoal activity is not an inherent feature of all saponins and that small variations in the structure of a compound can have a significant influence on their biological activity. Some sapogenins (20(S)-protopanaxatriol, asiatic acid and madecassic acid) inhibited protozoa activity to a greater extent than their corresponding saponins (Re and Rh1 and asiaticoside and madecassoside), thus the original hypothesis that the transient nature of the antiprotozoal action of saponins is due to the deglycosilation of saponins needs to be revisited.This work was supported by the Innovate UK project ‘Ivy for ruminants’ Ref:101091. CJN thanks the Biotechnology and Biological Sciences Research Council, UK via grant number BB/J0013/1, for financial support

Statistical analysis of the velocity field in a mechanical precessing jet flow

An experimental investigation of a precessing jet issuing from a mechanically rotating nozzle directed at an angle of α=45° relative to the axis of rotation is reported. Both conventional and conditional statistics of the velocity field of the jet were measured using a combined hot-wire and cold-wire (to identify any reverse flow) probe. Three distinct values (≈0.005, 0.01, and 0.02) of the precession Strouhal number Stp (≡ rotation frequency × nozzle diameter / jet exit bulk velocity) were used to assess the effect of varying Stp. The measurements reveal that the Strouhal number in general has significant influence on the entire mixing field generated by a precessing jet. The occurrence of precession at all the Strouhal numbers of investigation produces a central recirculation zone at x ≤ 7d, where x is a distance measured from the rotating nozzle exit. A critical Strouhal number, i.e., Stp,cr ≈0.008 for the present case, is identified: at Stp ≥ Stp,cr the core jet converges to the axis of rotation while at Stp ≥ Stp,cr it does not. The characteristics of the turbulent flow in the near and intermediate regions are quite different and depend upon the magnitude of Stp. The near-field region, x/d ≤ 10-15, is dominated by a regime of global precession of the entire jet. As a result, the large-scale entrainment of the ambient fluid is substantially enhanced while the fine-scale turbulent mixing is suppressed. Under the supercritical regime (i.e., Stp ≥ Stp,cr), the jet in the far field resembles some features of the nonprecessing counterpart. Nevertheless, significant differences still retain in the statistical properties. © 2005 American Institute of Physics.J. Mi and G. J. Natha

A demonstrator for a level-1 trigger system based on MicroTCA technology and 5Gb/s optical links

ABSTRACT: A demonstrator for the CMS Level-1 calorimeter trigger system has been designed, manufactured, tested and a time-multiplexed trigger implemented. The prototype card uses the AMC double width form factor, 5Gb/s links and a Xilinx XC5VTX150T or XC5VTX240T FPGA. A possible implementation of such a trigger architecture in CMS is described

Secondary school pupils' preferences for different types of structured grouping practices

The aim of this paper is to explore pupils’ preferences for particular types of grouping practices an area neglected in earlier research focusing on the personal and social outcomes of ability grouping. The sample comprised over 5,000 year 9 pupils (aged 13-14 years) in 45 mixed secondary comprehensive schools in England. The schools represented three levels of ability grouping in the lower school (years 7 to 9). Pupils responded to a questionnaire which explored the types of grouping that they preferred and the reasons for their choices. The majority of pupils preferred setting, although this was mediated by their set placement, type of school, socio-economic status and gender. The key reason given for this preference was that it enabled work to be matched to learning needs. The paper considers whether there are other ways of achieving this avoiding the negative social and personal outcomes of setting for some pupils

Run 2 Upgrades to the CMS Level-1 Calorimeter Trigger

The CMS Level-1 calorimeter trigger is being upgraded in two stages to maintain performance as the LHC increases pile-up and instantaneous luminosity in its second run. In the first stage, improved algorithms including event-by-event pile-up corrections are used. New algorithms for heavy ion running have also been developed. In the second stage, higher granularity inputs and a time-multiplexed approach allow for improved position and energy resolution. Data processing in both stages of the upgrade is performed with new, Xilinx Virtex-7 based AMC cards.Comment: 10 pages, 7 figure

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Background Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival. Whilst Sorafenib and Lenvatinib are now licenced for the treatment of progressive iodine refractory thyroid cancer, these treatments require continuing treatment and can be associated with significant toxicity. Evidence from a pilot study has demonstrated feasibility of Selumetinib to allow the reintroduction of I-131 therapy; this larger, multicentre study is required to demonstrate the broader clinical impact of this approach before progression to a confirmatory trial. Methods SEL-I-METRY is a UK, single-arm, multi-centre, two-stage phase II trial. Participants with locally advanced or metastatic differentiated thyroid cancer with at least one measureable lesion and iodine refractory disease will be recruited from 8 NHS Hospitals and treated with 4-weeks of oral Selumetinib and assessed for sufficient I-123 uptake (defined as any uptake in a lesion with no previous uptake or 30% or greater increase in uptake). Those with sufficient uptake will be treated with I-131 and followed for clinical outcomes. Radiation absorbed doses will be predicted from I-123 SPECT/CT and verified from scans following the therapy. 60 patients will be recruited to assess the primary objective of whether the treatment schedule leads to increased progression-free survival compared to historical control data. Discussion The SEL-I-METRY trial will investigate the effect of Selumetinib followed by I-131 therapy on progression-free survival in radioiodine refractory patients with differentiated thyroid cancer showing increased radioiodine uptake following initial treatment with Selumetinib. In addition, information on toxicity and dosimetry will be collected. This study presents an unprecedented opportunity to investigate the role of lesional dosimetry in molecular radiotherapy, leading to greater personalisation of therapy. To date this has been a neglected area of research. The findings of this trial will be useful to healthcare professionals and patients alike to determine whether further study of this agent is warranted. It is hoped that the development of the infrastructure to deliver a multicentre trial involving molecular radiotherapy dosimetry will lead to further trials in this field. Trial registration SEL-I-METRY is registered under ISRCTN17468602, 02/12/2015